Taysha Gene Therapies, Inc. Impairment of Long-Lived Assets Held-for-use
Taysha Gene Therapies, Inc. (TSHA) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-19
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $4.84M, a 685.39% increase year-over-year.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $4.84M, a 354.27% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $1.06M, a 97.08% decline from fiscal 2022.
- Taysha Gene Therapies, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $36.42M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 10-K · filed 2026-03-19 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.84M derived: sum of 2 quarters · filed 2026-03-19 | $4.84M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $4.84M 10-Q · filed 2025-11-04 | $4.84M 10-Q · filed 2025-11-04 | ||
| 2023-12-31 | $449.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $1.06M derived: sum of 2 quarters · filed 2025-02-26 | $1.06M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $616.00K 10-Q · filed 2024-11-13 | $616.00K 10-Q · filed 2024-11-13 | ||
| 2022-12-31 | $36.42M 10-K · filed 2024-03-19 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-28 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |